Not Yet RecruitingPhase 4

Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia

40 participantsStarted 2024-08-10

Plain-language summary

The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS. However, literature on the role of M-ECT in maintaining the therapeutic gains of acute ECT in CRS is lacking. The objective of the study is to compare the efficacy of M-ECT vs aripiprazole as an add-on to ongoing clozapine on the severity of symptom dimensions, cerebral perfusion, global functioning and cognitions in patients with CRS.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients clinically diagnosed with CRS (currently under clozapine)
✓. Patients aged 18-60 years of either sex.
✓. LAR giving voluntary written consent for participation in the study

Exclusion criteria

✕. Patient already on ECT or aripiprazole.
✕. History of psychoactive substance abuse or dependence.
✕. Co-morbid psychiatric, major medical or neurological disorders.
✕. History of organicity or significant head injury.
✕. Pacemaker or metal in any body part, excluding the mouth. Pregnant and breastfeeding females.

What they're measuring

Change in Positive And Negative Syndome Scale score

Timeframe: Baseline, 6 weeks, 12 weeks, 24 weeks

Trial details

NCT IDNCT06501339

SponsorAll India Institute of Medical Sciences, Bhubaneswar

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-31

Contact for this trial

Biswa Ranjan Mishra, MD

9438884220 psych_biswa@aiimsbhubaneswar.edu.in

View on ClinicalTrials.gov More Clozapine Resistant Schizophrenia trials